Acadia Pharmaceuticals diskutieren
Acadia Pharmaceuticals
WKN: 603035 / Symbol: ACAD / Name: ACADIA Pharm / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /
22,70 €
-1,01 %
ACADIA Pharmaceuticals (ACAD) had its price target raised by JPMorgan Chase & Co. from $31.00 to $34.00. They now have an "overweight" rating on the stock.
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals (ACAD) was upgraded by Bank of America Corporation from "neutral" to "buy". They now have a $29.00 price target on the stock.
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals (ACAD) had its price target lowered by Citigroup Inc. from $33.00 to $32.00. They now have a "buy" rating on the stock.
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals (ACAD) had its price target raised by Canaccord Genuity Group Inc. from $32.00 to $36.00. They now have a "buy" rating on the stock.
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals (ACAD) had its "buy" rating reaffirmed by Deutsche Bank Aktiengesellschaft.
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals (ACAD) had its price target raised by Bank of America Corporation from $29.00 to $30.00. They now have a "buy" rating on the stock.
Ratings data for ACAD provided by MarketBeat
Neueste Beiträge
StockNews_com in AbbVie Inc. diskutieren